Skip to main content
SpringerLink
Log in
Book cover

Coagulation in Cancer pp 279–293Cite as

Thrombocytopenia and Cancer

  • Chapter
  • First Online:

Part of the book series: Cancer Treatment and Research ((CTAR,volume 148))

Thrombocytopenia is frequently encountered in patients with solid tumors or hematologic malignancies. In these patients, it may be related to the underlying disease or it may be a consequence of treatment. In some cases, thrombocytopenia may be an isolated hematologic defect. However, thrombocytopenia in cancer patients will often be accompanied by variable amounts of anemia and/or neutropenia. In the majority of cases, thrombocytopenia in cancer patients is not clinically significant, but is discovered during routine blood counts. However, some of the causes of thrombocytopenia indicate the development of serious disorders which should be addressed promptly. Since the etiology of thrombocytopenia in cancer patients may be multifactorial, diagnosis is often complex. The main causes of thrombocytopenia are increased platelet destruction and decreased platelet production. Less frequent are splenic sequestration and dilutional thrombocytopenia.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Sun NC, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I: Coagulation studies. Am J Clin Pathol 1979;71:10–6

    PubMed  CAS  Google Scholar 

  2. Sallah S, Wan JY, Nguyen MP, et al. Disseminated intravascular coagulation in solid tumors: clinical and pathological study. Thromb Haemost 2001;86:828–33

    PubMed  CAS  Google Scholar 

  3. Taylor FB, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327–30

    PubMed  CAS  Google Scholar 

  4. Langer F, Spath B, Haubold K, et al. Tissue factor procoagulant activity of plasma microparticles in patients with cancer associated disseminated intravascular coagulation. Ann Hematol 2008;87:451–7

    Google Scholar 

  5. Sase T, Wada H, Yamaguchi M, et al. Hemostatic abnormalities and thrombotic disorders in malignant lymphoma. Thromb Haemost 2005;93:153–9

    PubMed  CAS  Google Scholar 

  6. Garg SK, Niemetx J. Tissue factor activity of normal and leukemic cells. Blood 1973;42:729–35

    PubMed  CAS  Google Scholar 

  7. Kakkar AK, DeRuvo N, Chinswangwatanakul V, et al. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995;346:1004–5

    Article  PubMed  CAS  Google Scholar 

  8. Edney JA, Hill A, Armstrong D. Peritoneovenous shunts palliate malignant ascites. Am J Surg. 1989;158:598–601

    Article  PubMed  CAS  Google Scholar 

  9. Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb Res 1975;6:127–37

    Article  PubMed  CAS  Google Scholar 

  10. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985;24:5558–65

    Article  PubMed  CAS  Google Scholar 

  11. Gordon SG, Cross BA. A factor X activating cysteine protease from malignant tissue. J Clin Invest 1981;67:1665–71

    Article  PubMed  CAS  Google Scholar 

  12. Falanga A, Alession MG, Donati MB, Barbui T. A new procoagulant in acute leukemia. Blood 1988;71:870–5

    PubMed  CAS  Google Scholar 

  13. Lorenzet R, Peri G, Locanti D, et al. Generation of procoagulant activity by mononuclear phagocytes: a possible mechanism contributing to blood clotting activation within malignant tissues. Blood 1983;62:271–3

    PubMed  CAS  Google Scholar 

  14. Donati MK, Gambarcoti-Passerini C, Casali B, et al. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res 1986;46:6471–4

    PubMed  CAS  Google Scholar 

  15. Juhan-Vague I, Valadier J, Alessi MC, et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987;57:67–72

    PubMed  CAS  Google Scholar 

  16. Hajjar KA. Fibrinolysis revisited: new insights into the pathobiology of cancer. Vessels 1996;2:9–16

    Google Scholar 

  17. Kockar C, Kockar O, Ozturk M, et al. Global fibrinolytic capacity increased exponentially in metastatic colorectal cancer. Clin Appl Thromb Hemost 2005;11:227–30

    Article  PubMed  CAS  Google Scholar 

  18. Sakata Y, Murakami T, Noro A, et al. The specific activity of plasminogen activator inhibitor 1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 1991;77:1949–57

    PubMed  CAS  Google Scholar 

  19. Wada H, Tamaki S, Tanigawa M, et al. Plasma level of IL-1 beta in disseminated intravascular coagulation. Thromb Haemost 1991;65:364–8

    PubMed  CAS  Google Scholar 

  20. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and anti-angiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320–7

    Article  PubMed  CAS  Google Scholar 

  21. Francis KK, Kalyanam N, Terrell DR, et al. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases. Oncologist 2007;12:11–19

    Article  PubMed  Google Scholar 

  22. Caramello V, Dovio A, Caraci P, et al. Thrombotic thrombocytopenic purpura in advanced prostate cancer: case report and published work review. Int J Urology 2007;14:150–2

    Article  CAS  Google Scholar 

  23. Furlan M, Robles R, Galbusera M, et al. A von Willebrand factor cleaving protease in thrombotic thrombocytopenia purpura and the hemolytic uremic syndrome. N Engl J Med 1998;339:1578–84

    Article  PubMed  CAS  Google Scholar 

  24. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002;100:4033–9

    Article  PubMed  CAS  Google Scholar 

  25. Oleksowicz L, Bhagwati N, DeLeon-Fernandez M. Deficient activity of von Willebrand’s factor cleaving protease in patients with disseminated malignancies. Cancer Res 1999;59:2244–50

    PubMed  CAS  Google Scholar 

  26. Mannucci PM, Karimi M, Mosalaei A, et al. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). Haematologica 2003;88:454–8

    PubMed  Google Scholar 

  27. Blot E, Decaudin D, Veyradier A, et al. Cancer-related thrombotic microangiopathy secondary to von Willebrand factor cleaving protease deficiency. Thromb Res 2002;106:127–30

    Article  PubMed  CAS  Google Scholar 

  28. Fontana S, Gerritsen HE, Kremer-Hovinga J, et al. Microangiopathic haemolytic anaemia in metastasizing malignant tumors is not associated with a severe deficiency of the von Willebrand factor cleaving protease. Br J Haematol 2001;113:100–2

    Article  PubMed  CAS  Google Scholar 

  29. Lohrmann HP, Adam W, Heymer B, et al. Microangiopathic hemolytic anemia in metastatic carcinoma: report of eight cases. Ann Intern Med 1973;79:368–75

    PubMed  CAS  Google Scholar 

  30. Kressel BR, Ryan, KP, Duong, AT, et al. Microangiopathic hemolytic anemia, thrombocytopenia and renal failure in patients treated for adenocarcinoma. Cancer 1981;48:1738–45

    Article  PubMed  CAS  Google Scholar 

  31. Koo BH, Oh D, Chung SY, et al. Deficiency of von Willebrand factor cleaving protease activity in the plasma of malignant patients. Thromb Res 2002;105:471–6

    Article  PubMed  CAS  Google Scholar 

  32. Hamilton CA, Kao JM, Coutre SE, Teng NN. Acute post operative thrombotic thrombocytopenic purpura following hysterectomy and lymphadenectomy for endometrial cancer. Gynecol Oncol 2007;106:423–6

    Article  PubMed  Google Scholar 

  33. Lesesne JB, Rothschild N, Erickson B, et al. Cancer associated hemolytic uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989;7:781–9

    PubMed  CAS  Google Scholar 

  34. Musso M, Porretto F, Crescimanno A, et al. Intense immunosuppressive therapy followed by autologous peripheral blood selected progenitor cell re-infusion for severe autoimmune disease. Am J Hematol. 2001;66:75–9

    Article  PubMed  CAS  Google Scholar 

  35. Zupancic M, Shah PC, Shah-Khan F. Gemcitibine-associated thrombotic thrombocytopenic purpura. Lancet 2007;8:634–41

    Article  CAS  Google Scholar 

  36. Werner TL, Agarwal N, Carney HM, Rodgers GM. Management of cancer associated thrombotic microangiopathy: what is the right approach. Am J Hematol 2007;82:295–8

    Google Scholar 

  37. Kirshner JJ, Zamkoff KW, Gottlieb AJ. Idiopathic thrombocytopenic purpura and Hodgkin’s disease: report of two cases and a review of the literature. Am J Med Sci 1980;280:21–8

    Article  PubMed  CAS  Google Scholar 

  38. Landogren O, Engles EA, Pfeiffer RM, et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population based case control study in Scandinavia. J Natl Cancer Inst 2006;98:1321–30

    Article  Google Scholar 

  39. Zaja F, Vianelli N, Sperotto A, et al. Anti-CD20 therapy for chronic lymphocytic leukemia associated autoimmune diseases. Leuk Lymphoma 2003;44:1951–5

    Article  PubMed  CAS  Google Scholar 

  40. Pamuk GE, Pamuk ON, Gaslar Z, et al. Overview of 321 patients with idiopathic thrombocytopenia purpura. Retrospective analysis of the clinical features and response to therapy. Ann Hematol 2002;81:436–40

    Article  PubMed  CAS  Google Scholar 

  41. Brighton TA, Evans S, Castaldi PA, et al. Prospective evaluation of the clinical usefulness of an antigen-specific assay in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996;88:194–201

    PubMed  CAS  Google Scholar 

  42. Warner MN, Moore JC, Warkentin TE, et al. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenia purpura. Br J Hematol 1999;104:442–7

    Article  CAS  Google Scholar 

  43. Porrata LF, Alberts S, Hook C, Hanson CA. Idiopathic thrombocytopenic purpura associated with breast cancer: a case report and review of the current literature. Am J Clin Oncol 1999;22:411–3

    Article  PubMed  CAS  Google Scholar 

  44. Ustun C, Dainer P, Hendricks L, et al. Association of breast cancer and immune thrombocytopenic purpura. South Med J 2002;95:1335–7

    PubMed  Google Scholar 

  45. Tarraza HM, Carroll R, De Cain M, Jones M. Recurrent ovarian carcinoma: presentation as idiopathic thrombocytopenic purpura and a spleen mass. Eur J Gynaecol Oncol 1991;12:439–43

    PubMed  CAS  Google Scholar 

  46. Amiral J, Peynaud-Debayle E, Wold M, et al. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with un-fractionated or low-molecular weight heparin. Am J Hematol 1996;52:90–5

    Article  PubMed  CAS  Google Scholar 

  47. Andreescu AC, Possidente C, Hsieh M, Cushman M. Evaluation of a pharmacy-based surveillance program for heparin-induced thrombocytopenia. Pharmacotherapy 2000;20:974–80

    Article  PubMed  CAS  Google Scholar 

  48. Laber DA, Martin MD. Etiology of thrombocytopenia in all patients treated with heparin products. Eur J Haematol 2005;75:101–5

    Article  PubMed  CAS  Google Scholar 

  49. Mureebe L, Silver D. Heparin-induced thrombocytopenia: pathophysiology and management. Vasc Endovascular Surg 2002;36:163–70

    Article  PubMed  Google Scholar 

  50. Rauova L, Zhai L, Kowalska MA, et al. Role of platelet surface PF4 antigenic complexes in heparin induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 2006;107:2346–53

    Article  PubMed  CAS  Google Scholar 

  51. Opatrny L, Warner MN. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol. 2004;76:240–4

    Article  PubMed  Google Scholar 

  52. Look KA, Sahud M, Flaherty S, Zehnder JL. Heparin-induced platelet aggregation vs platelet factor 4 enzyme-linked immunosorbent assay in the diagnosis of heparin induced thrombocytopenia. Am J Clin Pathol 1997;108:78–82

    PubMed  CAS  Google Scholar 

  53. Favaloro EJ, Bernal-Hoyos E, Exner T, Koutts J. Heparin induced thrombocytopenia: laboratory investigation and confirmation of diagnosis. Pathology 1992;24:177–83

    Article  PubMed  CAS  Google Scholar 

  54. Baldwin ZK, Spitzer AL, Ng VL, Harken AH. Contemporary standards for the diagnosis and treatment of heparin induced thrombocytopenia. Surgery 2008;143:305–12

    Article  PubMed  Google Scholar 

  55. Lubenow N, Eichler P, Lietz T, et al. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin induced thrombocytopenia; an analysis of 3 prospective studies. Blood 2004;104:3072–7

    Article  PubMed  CAS  Google Scholar 

  56. Rubins JM. The role of myelofibrosis in malignant leukoerythroblastosis. Cancer 1983;51:308–11

    Article  PubMed  CAS  Google Scholar 

  57. Makoni SN, Laber DA. Clinical spectrum of myelophthisis in cancer patients. Am J Hematol 2004;76:92–3

    Article  PubMed  Google Scholar 

  58. Tritz DB, Doll DE, Ringenberg QS, et al. Bone marrow involvement in small cell lung cancer. Clinical significance and correlation with routine laboratory variables. Cancer 1989;63:763–6

    Article  PubMed  CAS  Google Scholar 

  59. Prasad HK, Kaushal V, Mehta P. Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: case report and review of literature. Am J Hematol 2007;82:855–7

    Article  PubMed  Google Scholar 

  60. Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosomal aberrations in therapy related myelodysplastic syndromes in acute leukemia: overview report. Genes Chromosomes Cancer 2002;33:331–45

    Article  PubMed  Google Scholar 

  61. Smith SM, Le Beau MM, et al. Clinical cytogenetic associations in 306 patients with therapy related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102:43–52

    Article  PubMed  CAS  Google Scholar 

  62. Robinson RG, Blake GM, Preston DF, et al. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 1989;9:271–81

    PubMed  CAS  Google Scholar 

  63. Schiffer CA, Anderson IC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1519–38

    PubMed  CAS  Google Scholar 

  64. Pisciotto PT, Benson K, Hume H, et al. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 1995;35:498–502

    Article  PubMed  CAS  Google Scholar 

  65. Higby DJ, Cohen E, Holland JF, et al. The prophylactic treatment of thrombocytopenic leukemic patient with platelets: a double blind study. Transfusion 1974;14:440–6

    Article  PubMed  CAS  Google Scholar 

  66. Heckman KD, Weiner GJ, Davis CS, et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia 10,000 versus 20,000/μL. J Clin Oncol 1997;15:1143–9

    PubMed  CAS  Google Scholar 

  67. Rebulla P, Finazzi G, Marangoni F, et al. The Bruppo Italiano Malattie Ematologiche Maligne dell’Adulto; the threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997;337:1870–5

    Article  PubMed  CAS  Google Scholar 

  68. Wandt H, Frank M, Ehninger G, et al. Safety and cost effectiveness of a 10 × 109/L trigger for prophylactic platelet transfusions compared with the traditional 10 × 109/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998;91:3601–6

    PubMed  CAS  Google Scholar 

  69. Elting LS, Rubenstein EB, Martin CG, et al. Risk and outcomes of chemotherapy induced thrombocytopenia in solid tumor patients. Proc Am Soc Clin Oncol 1997;16;412.

    Google Scholar 

  70. Harkness DR, Byrnes JJ, Lian EC, et al. Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA 1981;246:1931–3

    Article  PubMed  CAS  Google Scholar 

  71. Coppa P, Lassoued K, Mariette X, et al. Effectiveness of platelet transfusions after plasma exchange in adult thrombotic thrombocytopenia purpura: a report of two cases. Am J Hematol 2001;68:198–201

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine of Northwestern University, Olsen 8524, 710 N Fairbanks Court, Chicago, Illinois 60611

    Elizabeth A. Eklund

Authors
  1. Elizabeth A. Eklund
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth A. Eklund .

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2009 Springer Science+Business Media, LLC

    About this chapter

    Cite this chapter

    Eklund, E.A. (2009). Thrombocytopenia and Cancer. In: Kwaan, H., Green, D. (eds) Coagulation in Cancer. Cancer Treatment and Research, vol 148. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-79962-9_16

    Download citation

    • DOI: https://doi.org/10.1007/978-0-387-79962-9_16

    • Published:

    • Publisher Name: Springer, Boston, MA

    • Print ISBN: 978-0-387-79961-2

    • Online ISBN: 978-0-387-79962-9

    • eBook Packages: MedicineMedicine (R0)

    Publish with us

    Policies and ethics

    Search

    Navigation